论文部分内容阅读
【目的】了解沙美特罗替卡松粉吸入剂(商品名:舒利迭)治疗中、重度儿童哮喘的临床治疗效果。【方法】收集了2009年1月-2010年3月本院哮喘门诊及住院的中、重度哮喘患儿46例,分别于吸入舒利迭治疗前及治疗3个月后,做肺通气功能及评价患儿临床控制情况。【结果】1)治疗3个月后肺通气功能明显改善:FEV1、PEF、FEF25、FEF50、FEF75、MMEF75/25治疗前分别为(1.31±0.59)、(3.05±1.33)、(2.39±1.17)、(1.30±0.69)、(0.52±0.28)、(1.08±0.60)L/S,吸入舒利迭治疗3个月后分别为(1.90±0.59)、(4.45±1.35)、(3.80±1.17)、(2.34±0.80)、(0.98±0.39)、(2.10±0.82)L/S(治疗前、后比较t值依次为4.80、5.02、5.78、6.67、6.57、6.80;P均<0.001);其中28例(60.9%)肺通气功能恢复正常,一项异常7例(15.2%),2项异常4例(8.7%),3项异常5例(10.9%),4项和5项异常各1例(2.2%),6项均异常0例;2)吸入舒利迭治疗3个月后87%(40例)的患儿达到临床控制,8.7%(4例)的患儿部分控制,4.3%(2例)未控制。【结论】吸入舒利迭可显著改善中、重度儿童哮喘临床症状及肺通气功能,是治疗年长儿童中、重度哮喘较为理想的药物,值得临床推广应用。
【Objective】 To investigate the clinical effects of salmeterol and fluticasone powder inhalation (trade name: seretide) in the treatment of moderate and severe asthma in children. 【Methods】 46 cases of moderate and severe asthma outpatients and hospitalized patients with asthma in our hospital from January 2009 to March 2010 were collected. Before and after treatment with seretide for 3 months, Evaluation of children with clinical control. 【Results】 1) After 3 months of treatment, the pulmonary function was significantly improved: (1.31 ± 0.59), (3.05 ± 1.33) and (2.39 ± 1.17) before treatment in FEV1, PEF, FEF25, FEF50, FEF75 and MMEF75 / , (1.30 ± 0.69), (0.52 ± 0.28) and (1.08 ± 0.60) L / S, respectively, and were 1.90 ± 0.59, 4.45 ± 1.35 and 3.80 ± 1.17 respectively , (2.34 ± 0.80), (0.98 ± 0.39) and (2.10 ± 0.82) L / S respectively (before and after treatment, the values of t were 4.80,5.02,5.78,6.67,6.57,6.80, P <0.001) Pulmonary ventilation returned to normal in 28 patients (60.9%), with one abnormality in 7 patients (15.2%), two abnormalities in 4 patients (8.7%), three abnormalities in 5 patients (10.9%), four and five abnormalities in 1 (2.2%), 6 cases were abnormal in 0 cases; 2) 87% (40 cases) of children achieved clinical control after inhalation of seretide for 3 months, and 8.7% (4 cases) % (2 cases) not controlled. 【Conclusion】 Inhaled seretide can significantly improve the clinical symptoms and pulmonary ventilation in asthmatic children with moderate and severe asthma. It is an ideal drug for the treatment of moderate and severe asthma in elderly children, and is worthy of clinical application.